Denali Therapeutics (DNLI) Change in Accured Expenses (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Change in Accured Expenses data on file, last reported at -$22.4 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 131.21% year-over-year to -$22.4 million in Q1 2026; TTM through Mar 2026 was -$12.2 million, a 39.79% decrease from a year earlier, with the FY2025 full-year figure at $465000.0, down 85.68% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$22.4 million, down from $12.7 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for DNLI reached as high as $24.6 million in Q3 2024 and fell as low as -$32.2 million in Q2 2023.
• Historically, Change in Accured Expenses has averaged -$300941.2 across 5 years, with a median of $1.9 million in 2025.
• Across the five-year window, Change in Accured Expenses tumbled 649.17% in 2023 and jumped 3249.59% in 2024, its largest moves.
• Year by year, Change in Accured Expenses stood at $4.0 million in 2022, then soared by 255.43% to $14.3 million in 2023, then slumped by 119.86% to -$2.8 million in 2024, then jumped by 547.82% to $12.7 million in 2025, then sank by 275.96% to -$22.4 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$22.4 million in Q1 2026, $12.7 million in Q4 2025, and $1.9 million in Q3 2025.